NASDAQ · OSRHW

OSR Health, Inc.

$0.04 -$0.01 (-13.18%) 1D Market open

Key Metrics

$479.87K
Market cap
P/E · TTM
$3.39M
Revenue · TTM
−$19.13M
Net income
EPS · TTM $-1.75
Dividend yield
Free cash flow
Beta · 1Y -0.46
EBITDA · TTM −$19.07M
Gross margin 17.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 23
    The stock moved +35.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 23
  • Apr 15
    From its Feb 2 high, the share price fell 50%.

    Peak close $0.06 on Feb 2; trough close $0.03 on Apr 15. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -50%
  • Apr 15
    The stock moved -37.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 15

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value−$617.02K
Shares outstanding
52-wk range$0.03 – $0.10
Avg volume · 20D42.3K
Net cash $1.10M
Book value / share$11.68
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About OSR Health, Inc.
IPO dateFeb 18, 2025
Employees22

OSR Health Inc is a healthcare holding company focused on biomedical technologies in health and wellness. Through its subsidiaries, the company engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes across various countries.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.14
P/FCF
EV/EBITDA
EV/Sales-0.18
Graham №

Profitability

Gross 17.2%
Operating -563.0%
Net -564.4%
FCF
ROE / ROIC -32.1% · -13.5%

Financial Health

Current ratio0.16
Quick ratio0.14
Debt / equity0.00
Debt / EBITDA -0.02
Net cash $1.10M
Working capital−$14.97M

Cash Flow · TTM

Operating CF −$5.27M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-0.8
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings